Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  2. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 755-762

2022

  1. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study

    Journal of Dermatological Treatment, Vol. 33, Núm. 3, pp. 1329-1338

2021

  1. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 1, pp. 60-71

  2. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study

    Journal of the European Academy of Dermatology and Venereology

2013

  1. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment

    Actas Dermo-Sifiliograficas